Table 1 Characteristics of P reserved R atio I mpaired S piro m etry (PRISm), smoking control, and COPD subjects in COPDGene using fixed threshold criteria

n

4388

1257

3690

Age

56.7 (8.4)*

57.2 (8.2)

63.4 (8.5)*

Sex (% Male)

52.9*

46.1

55.6*

African American

41.2

43.1

22.7*

Current smoker

59.7*

63.8

40.7*

Pack-years

37.2 (20.2)*

42.7 (24.2)

53.0 (27.5)*

Body Mass Index

28.9 (5.8)*

31.8 (7.3)

28.1 (6.3)*

FEV₁% predicted

97.5 (11.5)*

70.2 (8.4)

50.2 (18.0)*

FVC% predicted

96.6 (11.9)*

71.5 (9.1)

76.3 (17.3)*

FEV₁/FVC

0.79 (0.05)*

0.77 (0.05)

0.50 (0.13)*

Bronchodilator Responsiveness^†

10.0*

13.7

36.6*

Total Lung Capacity_CT% predicted

92.3 (14.6)*

79.9 (13.5)

101.5 (17.1)*

Segmental wall area percentage

60.1 (2.9)*

62.5 (3.1)

62.9 (3.1)*

Percent emphysema (% LAA-950_insp)

2.0 (2.5)*

1.4 (2.5)

13.0 (12.8)*

Percent gas trapping (% LAA-856_exp)

11.0 (9.7)

10.4 (9.1)

39.2 (20.8)*

Pi10

3.65 (0.11)*

3.73 (0.14)

3.72 (0.14)*

6 minute walk distance (feet)

1491.5 (350.7)*

1266.6 (366.9)

1174.8 (397.0)*

MMRC^‡ Dyspnea score

0.8 (1.2)*

1.5 (1.5)

2.1 (1.4)*

Resting O₂ saturation

97.1 (2.0)*

96.5 (2.5)

94.7 (3.6)*

Chronic bronchitis

12.6*

17.8

28.2*

Short acting beta-agonist use

12.0*

28.1

65.7*

Long acting beta-agonist use

4.4*

13.3

49.1*

Inhaled corticosteroid use

5.5*

16.4

51.2*

Oral corticosteroid use

0.5*

2

5.9*

Congestive heart failure

1.3*

4.6

5.4

Coronary artery disease

7.5*

13.5

16.5*

Diabetes mellitus

11.6*

21.6

13.1*

Hypertension

36.3*

49.1

50.6

Hyperlipidemia

34.3*

42.5

41.4

History of blood clot

2.8*

5.2

5.7

Peripheral vascular disease

1.3*

2.7

3.4

History of stroke

1.6*

3.5

3.6

Gastrointestinal reflux disease

20.3*

25.9

30.3*

History of compression fracture

3.4*

5.4

6.2

Currently employed

37.3*

28.9

25.3*

Physician-diagnosed asthma

11.4*

21.1

24.6*